BioLineRx Ltd. — Company profile
Healthcare · Biotechnology · Israel
Last price 1.99 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 10.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Details
| Name | BioLineRx Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 24 |
| Founded | 2003 |
| Ipo Date | 2011-07-25 |
| Ceo | Philip Serlin |
| Country | Israel |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US09071M3043 |
| Cusip | 09071M304 |
| Cik | 0001498403 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Philip A. Serlin C.P.A., M.B.A. | Chief Executive Officer |
| Mali Zeevi C.P.A. | Chief Financial Officer |
| Dr. Ella Sorani Ph.D. | Chief Development Officer |
| John Lacey | Head of Corporate Communications and Investor Relations |
| Raziel Fried | Treasurer and Budgetary Control Director |
Contact
| Address | Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, 7177871, Israel |
| Phone | 972 8 642 9100 |
| Website | https://www.biolinerx.com |